Latest news with #SanCarlos
San Francisco Chronicle
4 days ago
- San Francisco Chronicle
A ‘hidden gem' on San Francisco Bay is waiting to be explored
Sometimes, when the world closes in, the best thing to do is to go on a small adventure, perhaps to an island with trees, trails, beaches and wild animals — only a 30-minute ferry boat ride from the heart of the city. The destination is Angel Island State Park on the largest natural island in San Francisco Bay, perfect for a day trip into another world. It's accessible only by boat, so it has that unique feel that comes only to islands, a feeling of isolation. There are picnic areas and trails all over, little glens and benches to take in the spectacular view of San Francisco glittering across the bay, the Golden Gate Bridge and Mount Tamalpais. Angel Island is about the same size as Muir Woods National Monument, which draws over a million visitors a year and requires reservations. Angel Island has 200,000 visitors in a good year, so it's seldom crowded. 'Truly a hidden gem,' the state park website says. Casey Dexter-Lee, an interpretive ranger who has worked on Angel Island for 25 years, said more visitors are welcome. 'We ask people to tell their friends about Angel Island,' Dexter-Lee said. 'Tell three more people. It's truly a magical place.'' It's ideal for a quick escape, too. The Golden Gate Ferry runs four weekday round trips from the San Francisco Ferry Building, three on weekends. The Angel Island ferry runs three trips on weekdays in the summertime and six on weekends. The last boat leaves the island at 5 p.m.; there are no overnight accommodations unless you get a camping reservation. 'At night, you practically have the island to yourself,' one camper said. The island is a good place for exploring, too. The ferries land at Ayala Cove, where Spanish sea captain Juan Manuel de Ayala anchored the ship San Carlos in 1775, 250 years ago this August. The San Carlos was the first European ship to enter San Francisco Bay, and Ayala sent his pilot, Jose Canizares, to chart San Francisco Bay. He made the first survey of the bay and a copy of the chart is displayed in the old quarantine building near the ferry landing. The Spanish made contact with local Miwok people who welcomed them to their land. Little did they know what was to come. Ayala's ship was followed by British, Russian and American ships, by Mexican cattle ranchers and by Americans after 1846. The U.S. Army came during the Civil War to build a fort and gun battery on the west side of the island. Much of it is in ruins now, but some of the fort has been preserved. A bigger and better fort was built on the eastern side of the island — Fort McDowell, named for the Civil War general who was in command at Bull Run. Fort McDowell is a huge old concrete garrison, a hospital, a mess hall, a prison, spooky looking, abandoned and empty. If there are ghosts and bitter memories on the island, they are at the Immigration Station, where approximately 300,000 immigrants to the United States were detained between 1910 and 1940. About a third of them were Asian; 100,000 Chinese, 70,000 Japanese, 8,000 south Asian. There were also some Europeans: Russians fleeing the Bolsheviks, Jews escaping Nazis and political refugees without proper documents. It was a place of hope and despair; at Ellis Island in New York, Europeans were welcomed to the United States. At Angel Island, many Asians were turned away because of anti-Asian immigration laws. A sign near the main building describes it: 'Angel Island came to symbolize discrimination and exclusion instead of welcome.'' The immigration station and the barracks where the immigrants lived are a historic site and open to the public. But if Angel Island has its dark stories, it's hard to remember them on a sunny summer's day when people are hiking, riding bikes and eating lunch in the little café. 'I came here to work because it was a place I wanted to be,'' said Sandra Freeman, who is the general manager of the Angel Island Co., which runs the park concessions. 'It's slow on the weekdays, but you should come on the weekends. We'll have music, and we have a new chef. We'll have oysters.'' Weekdays were perfect for Dan Bednarczyk, one of the staff at the Ranch camp, a nonprofit based in Tiburon and Belvedere. He and other staffers were managing a gaggle of kids from San Francisco and Marin out on the island for a day camp. 'I have 142 kids today,' he said. 'We do different things, sometimes kayaking, sometimes hiking, sometimes a fashion show,' he said. 'Today is fishing day. We give them some cheese for bait and there they are.'' Sure enough, the camp staff had kids lined up on the boat dock with poles and hopeful expressions. Did they ever catch anything? Bednarczyk offered the enigmatic smile that is the hallmark of summer camp counselors the world over. 'Fishing teaches patience,'' he said. The children and adults who had spent the day on the island crowded on the boat sailing back to real life, full of tales they'd been told: how Angel Island has deer that come out at night, raccoons that live in the island forests, how a single coyote swam across Raccoon Strait from the Tiburon Peninsula one night in 2017. Then another coyote made the trip, a litter of pups followed and now Angel Island has a coyote population. One of Dexter-Lee's favorite stories is about the seldom seen Angel Island Mole, a mammal that lives underground. These moles — scientifically known as Scapanus latimanus insularis — evolved separately from mainland moles when the sea level rose about 10,000 years ago and the rising waters flooded the valley between what became an island and the Tiburon Peninsula. These island moles are slightly larger and have darker fur than their mainland brethren. 'This is the only place in the world they are found,' she said. That's what I like about Angel Island. It's one of a kind.
Associated Press
5 days ago
- Health
- Associated Press
Lions Host IGNITE: A Day for Youth to Empower the Next Generation to Lead, Learn, and Thrive
SAN CARLOS, CA - June 27, 2025 ( NEWMEDIAWIRE ) - The Lions of Region 5 - District 4-C4 today announce IGNITE: A Day for Youth, a powerful and immersive day-long experience dedicated to inspiring, equipping, and celebrating youth leadership, creativity, and well-being. DATE: Saturday, June 28, 2025 TIME: 10:00 AM – 3:00 PM LOCATION: Mahany Hall, 1336 Arroyo Avenue, San Carlos, CA IGNITE: A Day for Youth brings together teens and young adults with changemakers, mentors, mental health advocates, and civic leaders for a day of connection, inspiration, and action. 'IGNITE is an opportunity to inspire the next generation of leaders to find their purpose, power and possibility,' said Uni Buckley, event committee chair. 'We are honored to host these inspiring voices and to celebrate heroes nominated by young people.' Featured Speakers & Panelists Supervisor Noelia Corzo District 2 Supervisor, San Mateo County Board of Supervisors A lifelong resident of San Mateo County and the first Latina and Indigenous Supervisor in its history, Noelia Corzo brings a powerful story of public service, advocacy, and lived experience - from social work to elected leadership. Rowena Chiu #MeToo Activist & Survivor A former assistant to Harvey Weinstein and now a powerful global advocate, Rowena Chiu's journey from silence to international activism has inspired millions. Her story is featured in She Said, both the book and the film. Elona Kogan Executive, Board Member & Founder An accomplished leader in life sciences, Elona Kogan has driven over $10 billion in M&A activity while championing women in leadership, education, and the arts. Daniel Hornburg, Ph.D. VP, Biomarkers & Precision Medicine, Bruker Daniel Hornburg is a scientist, inventor, and precision medicine expert. From prion research to AI-driven diagnostics, his work proves that curiosity and science can truly change lives. Marc Rappaport Clinical Director, allcove San Mateo With over 20 years of service to underserved youth, Marc Rappaport leads a youth-driven wellness center that offers free mental, physical, and social health services for young people ages 12–25. Stacey Holmes Youth Program Coordinator, NAMI San Mateo County A Stanford MBA and former tech executive, Stacey Holmes leads the Ending the Silence program, helping students and communities confront stigma and support mental wellness. The event is free and open to the youth of San Mateo County. To register for the event which includes lunch, please contact Uni Buckley at (650) 892-2578. The event is made possible through the generous support and contributions of the following organizations: allcove San Mateo, Anson's Catering, BAGO Lions Club, Burlingame Lions Club, CUB Foundation, District 2 Office of the San Mateo County Board of Supervisors, First Republic Bank (now part of JPMorganChase), Foster City Lions Club, KT Soundz, Mahany Hall, NAMI San Mateo County, PRConnect, Redwood Shores Lions Club, Scott Marsters, and Silicon Valley Cyber Lions Club. About Lions International Lions International represents Lions Clubs International and Lions Clubs International Foundation. Lions take on some of the greatest challenges facing our communities and the world through the service of 1.4 million members in 49,000 clubs and the grant-funding support of our foundation. We improve health and well-being, strengthen communities and support those in need, locally and globally. At Lions International we are serving a world in need. Learn more about who we are and what we do at Media Contact Uni Buckley BAGO Lions Club (650) 892-2578 View the original release on
National Post
7 days ago
- Business
- National Post
BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day
Article content BRUKINSA, sonrotoclax, and BTK CDAC data, including combinations, are designed to comprehensively address unmet needs across CLL patient populations Article content Promising new data from pipeline assets in breast, lung, and GI cancer franchises, including CDK4 inhibitor, B7-H4 ADC, and novel PRMT5 inhibitor, will be featured Article content Pipeline is at an exciting inflection point with 20 near-term milestones in the next 18 months Article content SAN CARLOS, Calif. — In a significant showcase for investors, BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will announce major advancements to its industry-leading oncology pipeline during today's investor R&D Day. The event comes at a pivotal moment for the Company, which has more than 40 clinical and commercial stage assets in development, a signal of both scale and ambition. 'At BeOne, our mission is simple yet bold: to create the world's first next-generation oncology company,' said John V. Oyler, Co-Founder, Chairman, and CEO. 'What we will unveil demonstrates our progress towards this goal today, and the promise for tomorrow. From our innovative discovery engine to one of the broadest pipelines in oncology, we are well-positioned to bring transformative medicines to patients worldwide—and to do so with speed, quality, and purpose.' Article content BeOne's integrated, end-to-end R&D model is engineered for efficiency without compromise. The Company's differentiated approach—combining in-house discovery targeting unmet patient needs, parallel early-stage exploration at low incremental cost, and rapid proof-of-concept generation—enables swift progression from bench to clinic. Our in-house manufacturing around the world, including our flagship facility in Hopewell, NJ, means we have a sustainable business model, purpose built with competitive advantages. This rigorous model has fueled a pipeline of more than 40 clinical and commercial-stage assets, making it one of the most productive in the industry. To complement this research engine, BeOne has built a robust global clinical development platform, with more than 170 trials conducted across 40 countries and more than 25,000 patients enrolled to date. Article content In hematologic cancers, the Company's program is driven by its wholly-owned assets including BRUKINSA ® (zanubrutinib), a second-generation covalent BTK inhibitor and the backbone of the hematology franchise, sonrotoclax, a potential best-in-class next-generation BCL2 inhibitor, and BGB-16673, a BTK CDAC. New clinical data from CaDAnCe-101 highlight the promise of BGB-16673, a potential first-in-class BTK degrader, for patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia (CLL). Meanwhile, early data show the combination of sonrotoclax and BRUKINSA has demonstrated compelling efficacy and the potential to offer a best-in-class fixed-duration treatment in CLL, setting the stage for a possible new standard of care. Article content In solid tumors, the Company is advancing multiple targeted modalities beyond its foundational PD-1 inhibitor TEVIMBRA ® (tislelizumab-jsgr), including CDK4 inhibitor BGB-43395, which has shown clear pharmacodynamic activity and is expected to enter registration-enabling studies for the treatment of breast cancer within the next six to 12 months. Article content Promising new data for the B7-H4 ADC (BG-C9074) point to a potential first-in-class therapeutic option for patients with B7-H4 expressing tumors, including those without selection criteria. Additionally, early data from the novel PRMT5 inhibitor suggest a favorable safety profile and promising efficacy, supporting its potential for differentiation in the competitive lung cancer field. Article content 'Our R&D team is running at full speed,' said Lai Wang, Ph.D., Global Head of R&D. 'With more than 1,200 scientists and more than 3,700 clinical development and medical affairs colleagues dedicated to pushing the boundaries of oncology, we have built the infrastructure, mindset, and capabilities to deliver sustained innovation. The volume of clinical milestones we anticipate over the next few years is extraordinary, and our agility in moving from idea to execution sets us apart.' Article content Speakers at today's event include BeOne's executive leadership team, senior R&D leaders, and distinguished key opinion leaders, offering a multi-faceted view of the Company's scientific strategy and execution momentum. The live webcast begins at 8:30 a.m. U.S. Eastern Time and is available on the investor relations section of BeOne's website, where an archived version will also be accessible. Article content About BeOne Article content BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them. Article content Forward-Looking Statements Article content This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the future success of BeOne's pipeline assets; BeOne's ability to bring transformative medicines to patients worldwide with both speed and quality; the productivity of BeOne's pipeline; the ability of BeOne's assets to provide a new standard of care; the timing for BGB-43395 to enter registration-enabling studies; and BeOne's plans, commitments, aspirations, and goals under the heading 'About BeOne.' Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeOne's ability to obtain additional funding for operations and to complete the development of its drug candidates and maintain profitability; and those risks more fully discussed in the section entitled 'Risk Factors' in BeOne's most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law. Article content Article content Article content Article content Article content Contacts Article content
New York Times
02-06-2025
- General
- New York Times
Baby Shower Gifts That Parents-to-Be Don't Yet Know They Want
Michael Hession/NYT Wirecutter My twins are almost 19, and they still have their horsie lovies (in drawers by now, but still). Having a cozy little friend to hold and snuggle — especially for babies 6 months and up — provides comfort, soothing, and consistency. You have four different Pottery Barn Animal Thumbies to choose from, and each one has a squishy, bobbly head and a furry blanket body that's backed with a silky polyester satin. The ivory lamb version is a beloved confidant of editor Hannah Morrill's son — and over the years, she has bought a couple of backups when the original has gone AWOL. (Note to new parents: Lovies should be easily rebuyable to prevent heartbreak.) Crate Joy One never knows how banal bad children's books can truly be until they're stuck reading them interminably. Help build the baby's literary library with a monthly delivery of three books picked just for them by children's specialty bookstore The Reading Bug in San Carlos, California. At sign-up, indicate the child's name and age (the store has a newborn option) and a selection of topics that might be of interest to the parents, including subjects such as animals, humor, and music. Not sure? Don't worry, the booksellers at The Reading Bug have decades of experience putting award-winning, well-vetted, delightful books into even the tiniest hands. Choose a subscription of one, three, six, or 12 months. Michael Hession/NYT Wirecutter Expecting parents will receive all sorts of practical, useful items at their baby shower. But there is always room for the adorable and fun — because who on earth doesn't like dressing up their perfect new baby? The soft leather Bird Rock Baby Rose Gold Baby Moccasins (they also come in yellow gold and a rainbow of other colors) stay on little loaf feet and are perfect for new walkers who need to feel and grip the ground as they gain their balance. Each pair of Bird Rock Baby shoes is guaranteed for life, and for each pair sold the company donates the equivalent of a day's worth of food to Feed My Starving Children. Wee Gallery The bold and high-contrast graphics in the Wee Gallery Touch and Feel board books are the best we've found for engaging a baby in those early days. What's more, they also have varied tactile elements. Each one — Ears, Scales, Tails, and Wings — gives little fingers the opportunity to connect a physical sensation with the pictures and words on the page, from fuzzy bunny ears to a spongy lizard tail to a leathery bat wing. Yes, newborns aren't quite at that point yet, but as anyone who has ever raised a child knows, they'll be reaching out to touch stuff in what seems like a matter of moments. Unfortunately, though, these books are not sold as a set. Michael Hession/NYT Wirecutter Parents never know if they'll have a mouthy baby until their little drooly chomper is earthside. And that also means they're unlikely to register for teethers. Why not show up with the hand-painted Oli & Carol Ramona the Radish Baby Teether so they'll have it on hand for just such an occasion? Babies love this textured, 100%-natural-rubber teether because it has a bunch of different surfaces — ridged, curved, puffy, striated — for them to slurp and gnaw on. Parents love it because it's biodegradable, bacteria- and mold-resistant, and, well, kind of chic. On the off chance the discerning recipient finds radishes a touch bitter, perhaps Kendall the Kale or Pepa the Apple would be more to their liking. Michael Hession/NYT Wirecutter According to some medical studies and lots of good, old-fashioned folk wisdom, dates, which are rich in potassium, iron, magnesium, and selenium, can help shorten and ease labor. We can't vouch for that, personally or medically, but we can say that eating sticky, caramely, sweet dates certainly can't hurt the endeavor. Rancho Meladuco's The Due Date Bundle for Expectant Mothers comes in four- and six-week bundles. The four-week bundle includes four 2-pound boxes shipped two boxes at a time two weeks apart. Each box contains about 40 organic, unpitted Medjool dates, for a total of 160 dates — that's about five dates per day for the last month of pregnancy. And no matter where birth falls in that month, the morsels are a sweet and nourishing treat during new-baby days, too. Pearhead The easy-to-use, no-mess Pearhead Newborn Baby Handprint and Footprint Kit offers a simple way for new parents to capture prints of those itty-bitty hands and feet. (Tip from Wirecutter writer Brooklyn White: Do this before the baby enters the squirmy phase.) The kit comes with two no-mess, single-use, 3.5-by-2.5-inch ink pads. Place them face down on the included paper (or any paper the parents want to use), press the baby's hands or feet against the non-inked side, and voilà! The ink must dry for a day or two before it's completely set. No ink ever touches the baby's skin, and at $10 a pop, mess-ups aren't much of a setback. Lots of layette clothing is laughably impractical — think dry-clean-only cashmere with finicky buttons and itchy embellishments. That's what makes the Lewis Take Me Home Outfit so special. It's cute enough to be photographed endlessly (and to have those photos live on in infamy), but it's designed specifically for a smooshy, delicate new babe. The kimono styling of the top means a baby can be easily placed into it, and the footed pants have a high rise and a soft waist band, ideal for avoiding the belly button. It all washes wonderfully. January Moon The teething necklace fills three roles in one: It's something tough but chewy for babies to gnash their gums against, it's a hands-free distraction that won't get dropped and lost along the way, and it's a stylish necklace that actually looks like an intentional accessory when it's not being drooled on. The chunky silicone beads of the January Moon Saddle Signature Teething Necklace look like natural stone but are the perfect size, with lots of angles and nubs, for chewing. They're strung on Japanese polyester spindle rope, capped with 18-karat-gold-plated rubberized stopper beads, and finished with a food-safe plastic breakaway clasp. The necklace is 32 inches and comes in pastels, whites and grays, and some other designs, as well. Michael Hession/NYT Wirecutter Few things are more annoying — or dangerous for a partnership — than snapping a baby onesie in the middle of the night while your infant cries and you are suffering from sleep deprivation. The silent magnetic closures on these snuggly, soft, Tencel modal sleepers take all the fumbling out of the equation. Magnetic Me's Footies come in dozens of patterns and colors and are available in sizes from preemie to 18 months. At upwards of $40 a pop, though, they're expensive, especially for something that is destined to get telltale yellow stains — which is why they make such a generous and thoughtful gift. A wise and knowing professional friend gifted editor Hannah Morrill two sets postpartum for her first baby. 'We treated those like gold,' she says. 'There was no night we wanted to face without a clean pair on the ready.' Paige Tate & Co. Designed by Tabitha Paige, a licensed speech therapist and skilled watercolorist, the five sturdy board books in the sweet Our Little Library boxed set are artfully appointed to help babies develop language. These are not harsh academic drills for infants. They're beautiful illustrations of everyday things in five categories — farm animals, forest animals, fruits and vegetables, toys, and transportation — with a single word on each page. It's as much a gift for the parents as it is for the babe; if you're going to be gazing at a basket of blueberries at least 5,000 times, let it be a breathtakingly composed one. Michael Hession/NYT Wirecutter Yes, new parents will document their new baby's life on the cloud and the 'gram, in the family group chat, and in dozens of shared albums (or maybe all of the above). But the problem is, none of that is certain to be around when the bundle of joy is all grown-up and wants to cruise down memory lane. That's why we love Artifact Uprising's elegant The Story of You Baby Book. It's a lie-flat book filled with 50 thick, toothy pages of simple prompts — neither generic nor overly specific — plus photo spaces and pouches to help parents record events and occasions. Choose from seven combinations of linen colors and foil lettering. Each book comes with a coupon for 10 photo prints to get started. This article was edited by Hannah Morrill and Jennifer Hunter.
National Post
02-06-2025
- Business
- National Post
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025
Article content Article content Data underscore strength of emerging breast cancer pipeline as part of BeOne's global transformation with next wave of innovation Article content SAN CARLOS, Calif. — BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Poster presentations feature preliminary results of the dose escalation studies of two investigational molecules: BG-C9074, a novel B7-H4-targeting antibody-drug conjugate (ADC) in patients with advanced solid tumors, including breast cancer, and BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), in HR+/HER2- breast cancer patients with prior CDK4/6i exposure. Article content 'Presenting the first clinical data for two novel breast cancer candidates at ASCO 2025 marks a pivotal moment for BeOne,' said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne. 'These early results highlight the strong potential of our B7-H4-targeting ADC and CDK2 inhibitor to address critical gaps in breast cancer treatment. Alongside our advancing CDK4 inhibitor, they represent just the beginning of a pipeline built on targeted, biology-driven innovation. As we debut our new identity as BeOne, this milestone reflects the momentum behind our science and our commitment to delivering impactful therapies to cancer patients worldwide.' Article content BeOne is advancing a robust pipeline of differentiated investigational medicines for breast cancer that may both effectively combat the disease and potentially improve quality of life for patients receiving treatment. Article content BeOne presented initial results of the ongoing first-in-human, Phase 1a dose escalation study of BG-C9074 monotherapy in 78 patients with advanced solid tumors, of which more than a quarter were breast cancer patients. BG-C9074, an investigational topoisomerase I inhibitor ADC that targets the B7-H4 protein, which is broadly expressed in breast and gynecologic cancers, is designed with an innovative drug linker to deliver a potent cancer-killing drug directly to the cancer cells. Article content With limited follow-up among the 56 efficacy-evaluable patients, preliminary clinical responses were observed at multiple dose levels across various tumor types without selection for B7-H4 expression in these heavily pretreated patients. Confirmed overall response rate (ORR) was 16.1% (9/56; 95% CI: 7.6%–28.3%), with 9 confirmed partial responses; unconfirmed ORR was 25.0% (14/56; 14.4%-38.4%) (n=14 partial responses). Confirmed disease control rate (DCR) was 73.2% (59.7%-84.2%) and confirmed clinical benefit rate (CBR) was 17.9% (8.9%-30.4%). Pharmacokinetics (PK) were observed to be approximately dose-proportional across dose levels. Article content BG-C9074 showed a manageable safety and tolerability profile in patients with B7-H4 advanced solid tumors, including breast cancer. There were 5 dose-limiting toxicities (DLTs) reported among 3 dose levels, all related to treatment: grade 3 fatigue (n=1); grade 3 febrile neutropenia (n=2); and grade 4 platelet count decreased (n=2). The most common treatment-emergent adverse events (TEAEs) were nausea, fatigue, and neutropenia*. The most common grade ≥3 TEAEs were neutropenia and thrombocytopenia†. There were no TEAEs leading to treatment discontinuation or death. Article content Dose-escalation data from the first-in-human, Phase 1a study of a novel CDK2 inhibitor, BG-68501, were presented as a poster today. BG-68501 is designed to address elevated CDK2 activity as well as cyclin E1-driven upregulation, two key resistance mechanisms that often limit the effectiveness of CDK4/6 inhibitors in treating HR+/HER2- breast cancer. CDK inhibitors target checkpoint proteins that control cell division to stop the growth of cancer cells. Article content A total of 57 enrolled patients with advanced solid tumors, including 19 patients with HR+/HER2- metastatic breast cancer, received BG-68501 as monotherapy or in combination with fulvestrant in escalating dose cohorts (all received prior CDK4/6i). Article content Of the 37 efficacy-evaluable patients (all with monotherapy), unconfirmed overall response rate (ORR) was 5.4% (2/37; 95% CI: 0.7%–18.2%). Two extensively pretreated patients (5.4%) experienced unconfirmed partial response (PR), 15 patients (40.5%) had stable disease (SD), 15 patients (40.5%) had progressive disease (PD), and 5 patients (13.5%) were not evaluable/not assessed. Of the 2 patients with PR, both were breast cancer patients, and one was ongoing with treatment at the time of data cutoff, while the other had discontinued treatment. Unconfirmed clinical benefit rate (CBR) was 8.1% (3/37; 95% CI: 1.7%-21.9%) and unconfirmed disease control rate (DCR) was 45.9% (17/37; 95% CI: 29.5%-63.1%). BG-68501 demonstrated a linear PK profile consistent with preclinical data and signs of pharmacodynamic responses. Article content BG-68501 demonstrated a manageable safety and tolerability profile, with no DLTs observed to date during dose escalation. The most common TEAEs were vomiting, nausea, and fatigue, and TEAEs leading to treatment discontinuation occurred in 4 patients (7%) across all dose levels. There were no TEAEs leading to death. Article content The data support continued development of BG-68501 as a next-line option for tumors with CDK2 dependency. ( NCT06257264) Article content For additional information about our presence at the 2025 ASCO Annual Meeting, please visit our meeting hub: Article content BeOne will host an investor R&D Day on June 26 at 8:30 am ET covering its deep and broad global innovation pipeline and platforms, as well as the Company's vision, differentiated capabilities, and value creation drivers. A live webcast will be accessible from the investors section of BeOne's website at or An archived replay will be available for 90 days following the event. Article content BeOne is advancing a robust portfolio of investigational medicines for breast cancer, including three molecules in clinical development – two cyclin-dependent kinase (CDK) inhibitors, BGB-43395, a CDK4 inhibitor, and BG-68501, a CDK2 inhibitor, and an antibody-drug conjugate (ADC), BG-C9074. BeOne also plans to evaluate the potential of BCL2 inhibition in breast cancer, with next-generation BCL2 inhibitor, BGB-21447, expected to begin clinical testing in solid tumor indications soon. Multispecific antibodies and targeted protein degraders with potential applications in breast cancer are among the preclinical assets being developed. Article content About Breast Cancer Article content Breast cancer accounts for close to one in four cancer cases and one in six cancer deaths in women worldwide. 1 Globally, breast cancer is the second most common cancer and the fourth highest cause of cancer mortality as well as the leading cause of cancer death in women. 1 More than 2.3 million patients were diagnosed with breast cancer in 2022, and over 666,000 deaths were reported globally. 1 Approximately two-thirds of breast cancer cases are the HR+/HER2- subtype. 2 Article content About BeOne Article content BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them. Article content This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the potential of BeOne's B7-H4-targeting ADC and CDK2 inhibitor to address critical gaps in breast cancer treatment; the ability of BeOne to deliver impactful therapies to cancer patients worldwide; the ability of BeOne's pipeline to effectively combat breast cancer and improve quality of life for patients; and BeOne's plans, commitments, aspirations, and goals under the heading 'About BeOne.' Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and maintain profitability; and those risks more fully discussed in the section entitled 'Risk Factors' in BeOne's most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law. Article content *Neutropenia was defined by a custom MedDRA basket with neutropenia and neutrophil count decrease preferred terms. Article content †Thrombocytopenia was defined by a custom MedDRA basket with thrombocytopenia and platelet count decreased preferred terms. Article content Article content Article content Article content Article content Contacts Article content Article content Article content
